董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Karen S. Lynch | 女 | Chief Executive Officer and President and Director | 61 | 2161.50万美元 | 43.14 | 2024-04-05 |
| Alecia A. DeCoudreaux | 女 | Independent Director | 69 | 30.15万美元 | 0.30 | 2024-04-05 |
| Mary L. Schapiro | 女 | Independent Director | 68 | 30.15万美元 | 1.18 | 2024-04-05 |
| Anne M. Finucane | 女 | Independent Director | 71 | 32.15万美元 | 3.24 | 2024-04-05 |
| Jean Pierre Millon | 男 | Independent Director | 73 | 32.15万美元 | 10.77 | 2024-04-05 |
| Fernando Aguirre | 男 | Independent Director | 66 | 31.82万美元 | 3.28 | 2024-04-05 |
| Roger N. Farah | 男 | Independent Director | 71 | 57.65万美元 | 0.41 | 2024-04-05 |
| C. David Brown, II | 男 | Independent Director | 72 | 32.15万美元 | 11.91 | 2024-04-05 |
| Michael F. Mahoney | 男 | Independent Director | 59 | 16.75万美元 | 0.22 | 2024-04-05 |
| Nancy Ann M. DeParle | 女 | Independent Director | 67 | 32.15万美元 | 2.95 | 2024-04-05 |
| J. Scott Kirby | 男 | Independent Director | 56 | 19.54万美元 | 0.27 | 2024-04-05 |
| Jeffrey R. Balser | -- | Independent Director | 62 | 30.15万美元 | 0.51 | 2024-04-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Karen S. Lynch | 女 | Chief Executive Officer and President and Director | 61 | 2161.50万美元 | 43.14 | 2024-04-05 |
| James D. Clark | -- | Senior Vice President - Controller and Chief Accounting Officer | 59 | 未披露 | 未持股 | 2024-04-05 |
| Laurie P. Havanec | 女 | Executive Vice President and Chief People Officer | 63 | 未披露 | 未持股 | 2024-04-05 |
| Prem Shah | -- | Executive Vice President and Chief Pharmacy Officer | 44 | 858.24万美元 | 3.47 | 2024-04-05 |
| Tilak Mandadi | 男 | Executive Vice President and Chief Data, Digital and Technology Officer | 60 | 888.18万美元 | 2.02 | 2024-04-05 |
| Sreekanth K. Chaguturu | -- | Executive Vice President and Chief Medical Officer | 45 | 未披露 | 未持股 | 2024-04-05 |
| Thomas F. Cowhey | 男 | Executive Vice President and Chief Financial Officer | 52 | 457.99万美元 | 2.86 | 2024-04-05 |
| Brian A. Kane | -- | Executive Vice President | 51 | 未披露 | 未持股 | 2024-04-05 |
| J. David Joyner | -- | Executive Vice President | 59 | 未披露 | 未持股 | 2024-04-05 |
| Samrat S. Khichi | 男 | Executive Vice President, Chief Policy Officer and General Counsel | 57 | 1188.65万美元 | 0.98 | 2024-04-05 |
董事简历
中英对照 | 中文 | 英文- Karen S. Lynch
-
Karen S. Lynch，是Aetna Inc.（一家多元医疗保健利益公司）总裁。她自2014年起担任总裁。她从2013年到2014年担任Aetna's Local and Regional业务执行副总裁；2012年到2013年担任Aetna's Specialty Products业务执行副总裁。Lynch从2009年到2012年担任Magellan Health Services Inc.（一家医疗保健管理公司）总裁。加入Magellan Health之前，她从1999年到2009年在Cigna Corporation（一家全球健康保险服务公司）担任多个领导职位。
Karen S. Lynch,President and Chief Executive Officer of CVS Health Corporation since February 2021; Executive Vice President of CVS Health Corporation from November 2018 through January 2021; President of Aetna Inc. from January 2015 through January 2021; and a director of CVS Health Corporation since February 2021. - Karen S. Lynch，是Aetna Inc.（一家多元医疗保健利益公司）总裁。她自2014年起担任总裁。她从2013年到2014年担任Aetna's Local and Regional业务执行副总裁；2012年到2013年担任Aetna's Specialty Products业务执行副总裁。Lynch从2009年到2012年担任Magellan Health Services Inc.（一家医疗保健管理公司）总裁。加入Magellan Health之前，她从1999年到2009年在Cigna Corporation（一家全球健康保险服务公司）担任多个领导职位。
- Karen S. Lynch,President and Chief Executive Officer of CVS Health Corporation since February 2021; Executive Vice President of CVS Health Corporation from November 2018 through January 2021; President of Aetna Inc. from January 2015 through January 2021; and a director of CVS Health Corporation since February 2021.
- Alecia A. DeCoudreaux
-
Alecia A. DeCoudreaux自2011年7月以来是Mills College（男性和女性研究生项目的女性文理学院）的总裁。此前，她在Eli Lilly and Company（Eli Lilly）（全球药品制造商）担任许多领导角色，包括专业法律团队的副总裁和副总法律顾问（从2010年到2011年），Lilly美国的副总裁兼总法律顾问（从2005年到2009年），Eli Lilly的秘书、副总法律顾问（从1999年到2005年）。在Eli Lilly的30年职业生涯中，她也曾担任Lilly Research Laboratories的执行董事，联邦政府关系的主管，国家政府关系的主管和社区关系的主管。此外，她曾服务于一些慈善、教育、盈利和非盈利董事会，包括担任Wellesley College的理事和董事会主席。
Alecia A. DeCoudreaux is President Emerita of Mills College, a liberal arts college for women with graduate programs for women and men, having served a five-year term as President from July 2011 through June 2016. Previously, Ms. DeCoudreaux served in a number of leadership roles at Eli Lilly and Company, a global pharmaceutical manufacturer "Eli Lilly", including as Vice President and Deputy General Counsel, Specialty Legal Team, from 2010-2011 Vice President and General Counsel, Lilly USA, from 2005-2009 and Secretary and Deputy General Counsel of Eli Lilly from 1999-2005. During her 30-year career with Eli Lilly, Ms. DeCoudreaux also previously served as Executive Director of Lilly Research Laboratories, Director of Federal Government Relations, Director of State Government Relations and Director of Community Relations. In addition, Ms. DeCoudreaux has served on a number of charitable, educational, for profit and nonprofit boards, including as both a trustee and board chair at Wellesley College. She currently serves as Lead Independent Trustee and Chairperson of the Board of Trustees of Parnassus Funds and Parnassus Income Funds, each a family of investment funds that integrates ESG factors and fundamental investment principles. - Alecia A. DeCoudreaux自2011年7月以来是Mills College（男性和女性研究生项目的女性文理学院）的总裁。此前，她在Eli Lilly and Company（Eli Lilly）（全球药品制造商）担任许多领导角色，包括专业法律团队的副总裁和副总法律顾问（从2010年到2011年），Lilly美国的副总裁兼总法律顾问（从2005年到2009年），Eli Lilly的秘书、副总法律顾问（从1999年到2005年）。在Eli Lilly的30年职业生涯中，她也曾担任Lilly Research Laboratories的执行董事，联邦政府关系的主管，国家政府关系的主管和社区关系的主管。此外，她曾服务于一些慈善、教育、盈利和非盈利董事会，包括担任Wellesley College的理事和董事会主席。
- Alecia A. DeCoudreaux is President Emerita of Mills College, a liberal arts college for women with graduate programs for women and men, having served a five-year term as President from July 2011 through June 2016. Previously, Ms. DeCoudreaux served in a number of leadership roles at Eli Lilly and Company, a global pharmaceutical manufacturer "Eli Lilly", including as Vice President and Deputy General Counsel, Specialty Legal Team, from 2010-2011 Vice President and General Counsel, Lilly USA, from 2005-2009 and Secretary and Deputy General Counsel of Eli Lilly from 1999-2005. During her 30-year career with Eli Lilly, Ms. DeCoudreaux also previously served as Executive Director of Lilly Research Laboratories, Director of Federal Government Relations, Director of State Government Relations and Director of Community Relations. In addition, Ms. DeCoudreaux has served on a number of charitable, educational, for profit and nonprofit boards, including as both a trustee and board chair at Wellesley College. She currently serves as Lead Independent Trustee and Chairperson of the Board of Trustees of Parnassus Funds and Parnassus Income Funds, each a family of investment funds that integrates ESG factors and fundamental investment principles.
- Mary L. Schapiro
-
Mary L. Schapiro，自2018年10月起担任彭博公司（Bloomberg L.P.）的创始人和董事长的全球公共政策副主席和特别顾问。自2014年1月起，担任Promontory Financial Group LLC（领先的战略、风险管理和监管合规公司）咨询委员会副主席。2013年4月至2014年1月，她是治理和市场实践主席岬金融集团董事。自2014年5月起担任可持续会计标准基金会董事会副主席。2009年1月至2012年12月，担任美国证券交易委员会（SEC）主席。2006年至2008年，担任金融业监管局（FINRA）主席兼首席执行官；1996年至2006年，担任FINRA及其前身公司的许多其他关键执行职位，包括NASD Regulation的副主席兼总裁。1994年至1996年，担任商品期货交易委员会（CFTC）主席。她毕业于富兰克林与马歇尔大学和在乔治华盛顿大学法学院获得法学学位。
Mary L. Schapiro,Vice Chair for Global Public Policy and Special Advisor to the Founder and Chair of Bloomberg L.P. since October 2018.Vice Chair of the Advisory Board of Promontory Financial Group LLC (Promontory), a leading strategy, risk management and regulatory compliance firm, from January 2014 through 2018. Managing Director of Promontory from April 2013 to January 2014.Vice Chair of the Value Reporting Foundation Board from June 2021 to August 2022, and the Sustainability Accounting Standards Board from May 2014 to June 2021.Chair of the SEC from January 2009 to December 2012.Chair and CEO of the Financial Industry Regulatory Authority (FINRA), from 2006 to 2008, and served in numerous other key executive positions at FINRA and its predecessor from 1996 to 2006, including Vice Chair and President of NASD Regulation.Chair of the Commodity Futures Trading Commission (CFTC) from 1994 to 1996.Franklin & Marshall College, Bachelor's Degree.The George Washington University Law School, Juris Doctor. - Mary L. Schapiro，自2018年10月起担任彭博公司（Bloomberg L.P.）的创始人和董事长的全球公共政策副主席和特别顾问。自2014年1月起，担任Promontory Financial Group LLC（领先的战略、风险管理和监管合规公司）咨询委员会副主席。2013年4月至2014年1月，她是治理和市场实践主席岬金融集团董事。自2014年5月起担任可持续会计标准基金会董事会副主席。2009年1月至2012年12月，担任美国证券交易委员会（SEC）主席。2006年至2008年，担任金融业监管局（FINRA）主席兼首席执行官；1996年至2006年，担任FINRA及其前身公司的许多其他关键执行职位，包括NASD Regulation的副主席兼总裁。1994年至1996年，担任商品期货交易委员会（CFTC）主席。她毕业于富兰克林与马歇尔大学和在乔治华盛顿大学法学院获得法学学位。
- Mary L. Schapiro,Vice Chair for Global Public Policy and Special Advisor to the Founder and Chair of Bloomberg L.P. since October 2018.Vice Chair of the Advisory Board of Promontory Financial Group LLC (Promontory), a leading strategy, risk management and regulatory compliance firm, from January 2014 through 2018. Managing Director of Promontory from April 2013 to January 2014.Vice Chair of the Value Reporting Foundation Board from June 2021 to August 2022, and the Sustainability Accounting Standards Board from May 2014 to June 2021.Chair of the SEC from January 2009 to December 2012.Chair and CEO of the Financial Industry Regulatory Authority (FINRA), from 2006 to 2008, and served in numerous other key executive positions at FINRA and its predecessor from 1996 to 2006, including Vice Chair and President of NASD Regulation.Chair of the Commodity Futures Trading Commission (CFTC) from 1994 to 1996.Franklin & Marshall College, Bachelor's Degree.The George Washington University Law School, Juris Doctor.
- Anne M. Finucane
-
Anne M. Finucane，她自2006年起出任国际投资服务公司美国银行全球战略与营销官，2004年起，出任美国银行东北市场部总裁。在她作为高级管理人员为美国银行效劳的十八年里，她曾为首席执行官及董事会成员提供建议的资深顾问，并专注于企业战略和公共决策的制定与推行。她主要负责监管营销，公共策略，政府事务，消费者政策及企业社会责任感，领导美国银行国内外政策与问题方面的解决提案以及定位其他影响着美国银行的公共事务和金融服务产业。
Anne M. Finucane has been Chairman of the Board of Bank of America Europe DAC since July 2018. Ms. Finucane served as a Vice Chairman of Bank of America Corporation, an international financial services company, from July 2015 until her retirement in December 2021. From 2006 through July 2015 Ms. Finucane served as Global Chief Strategy and Marketing Officer for Bank of America and served as Northeast Market President from 2004 through July 2015. During her 20-plus years as a senior leader at Bank of America and its legacy firms, Ms. Finucane served as senior advisor to four chief executive officers and the Board of Directors. As a member of the executive management team, Ms. Finucane was responsible for the strategic positioning of Bank of America and led the company's environmental, social and governance, sustainable finance, capital deployment and public policy efforts. She was chair of Bank of America's Environmental, Social and Governance Committee, which directs all of its ESG efforts, and the Capital Deployment Group, which collaborates across business lines to deliver innovative financing solutions to address global issues. Ms. Finucane stewarded Bank of America's $300 billion environmental business initiative, oversaw the company's $1.6 billion Community Development Financial Institution portfolio and chaired the Bank of America Charitable Foundation. She currently serves as a director of Williams Sonoma, Inc., a retailer of kitchen and home products. - Anne M. Finucane，她自2006年起出任国际投资服务公司美国银行全球战略与营销官，2004年起，出任美国银行东北市场部总裁。在她作为高级管理人员为美国银行效劳的十八年里，她曾为首席执行官及董事会成员提供建议的资深顾问，并专注于企业战略和公共决策的制定与推行。她主要负责监管营销，公共策略，政府事务，消费者政策及企业社会责任感，领导美国银行国内外政策与问题方面的解决提案以及定位其他影响着美国银行的公共事务和金融服务产业。
- Anne M. Finucane has been Chairman of the Board of Bank of America Europe DAC since July 2018. Ms. Finucane served as a Vice Chairman of Bank of America Corporation, an international financial services company, from July 2015 until her retirement in December 2021. From 2006 through July 2015 Ms. Finucane served as Global Chief Strategy and Marketing Officer for Bank of America and served as Northeast Market President from 2004 through July 2015. During her 20-plus years as a senior leader at Bank of America and its legacy firms, Ms. Finucane served as senior advisor to four chief executive officers and the Board of Directors. As a member of the executive management team, Ms. Finucane was responsible for the strategic positioning of Bank of America and led the company's environmental, social and governance, sustainable finance, capital deployment and public policy efforts. She was chair of Bank of America's Environmental, Social and Governance Committee, which directs all of its ESG efforts, and the Capital Deployment Group, which collaborates across business lines to deliver innovative financing solutions to address global issues. Ms. Finucane stewarded Bank of America's $300 billion environmental business initiative, oversaw the company's $1.6 billion Community Development Financial Institution portfolio and chaired the Bank of America Charitable Foundation. She currently serves as a director of Williams Sonoma, Inc., a retailer of kitchen and home products.
- Jean Pierre Millon
-
Jean Pierre Millon，他是PCS Health Systems, Inc.的已退休总裁和首席执行官。1995年，他加入PCS，1996年6月至2000年9月退休，担任总裁和首席执行官。2012年4月从董事会离职之前，他担任InfuSystems Holdings, Inc.的董事， 该公司是泵、物资和肿瘤实践与诊所支持供应商；2010年8月从董事会离职之前，担任生物技术公司Cypress Bioscience, Inc.的董事。2004年3月Caremark收购AdvancePCS起，他担任Caremark Rx, Inc.的董事会成员；2000年10月起，担任AdvancePCS （由PCS与Advance Paradigm, Inc.合并组成）的董事。CVS与Caremark合并结束后，他成为CVS Caremark的董事。
Jean Pierre Millon is the former President and Chief Executive Officer of PCS Health Systems, Inc. "PCS", a pharmacy benefit management company. Mr. Millon joined PCS in 1995 where he served as President and Chief Executive Officer from June 1996 until his retirement in September 2000. Prior to that, Mr. Millon served as an executive of and held several global leadership positions with Eli Lilly and Company, a global pharmaceutical manufacturer. Mr. Millon previously served on the board of Caremark from March 2004 upon Caremark's acquisition of AdvancePCS, and as a director of AdvancePCS (which resulted from the merger of PCS and Advance Paradigm, Inc.) beginning in October 2000. He became a director of CVS Health upon the closing of the merger transaction involving CVS Health and Caremark. - Jean Pierre Millon，他是PCS Health Systems, Inc.的已退休总裁和首席执行官。1995年，他加入PCS，1996年6月至2000年9月退休，担任总裁和首席执行官。2012年4月从董事会离职之前，他担任InfuSystems Holdings, Inc.的董事， 该公司是泵、物资和肿瘤实践与诊所支持供应商；2010年8月从董事会离职之前，担任生物技术公司Cypress Bioscience, Inc.的董事。2004年3月Caremark收购AdvancePCS起，他担任Caremark Rx, Inc.的董事会成员；2000年10月起，担任AdvancePCS （由PCS与Advance Paradigm, Inc.合并组成）的董事。CVS与Caremark合并结束后，他成为CVS Caremark的董事。
- Jean Pierre Millon is the former President and Chief Executive Officer of PCS Health Systems, Inc. "PCS", a pharmacy benefit management company. Mr. Millon joined PCS in 1995 where he served as President and Chief Executive Officer from June 1996 until his retirement in September 2000. Prior to that, Mr. Millon served as an executive of and held several global leadership positions with Eli Lilly and Company, a global pharmaceutical manufacturer. Mr. Millon previously served on the board of Caremark from March 2004 upon Caremark's acquisition of AdvancePCS, and as a director of AdvancePCS (which resulted from the merger of PCS and Advance Paradigm, Inc.) beginning in October 2000. He became a director of CVS Health upon the closing of the merger transaction involving CVS Health and Caremark.
- Fernando Aguirre
-
Fernando Aguirre从2004年1月至2012年10月担任Chiquita Brands International, Inc.（消费产品的全球经销商）的总裁兼首席执行官，2004年5月至2012年10月担任主席。加入Chiquita之前，他在The Procter & Gamble Company（P&G）（消费产品的制造商和分销商）的品牌管理、综合管理和转场领域工作超过23年。他于1980年开始他在P&G的职业生涯，担任各种职位，包括P&G Brazil的总裁和总经理，P&G Mexico的总裁，P&G全球零食和美国食品的副总裁，全球女性护理的总裁。他在2002年7月被任命为特殊项目的总裁，为P&G的主席和首席执行官提供报告，负责策略。他从2005年到2010年11月是Coca-Cola Enterprises Inc.的董事。
Fernando Aguirre has been a director since July 2019. He served as President and CEO of Chiguita Brands International, Inc. from January 2004 to October 2012 and also served as Chairman from May 2004 to October 2012. Prior to that, Mr. Aguirre held various global marketing and management roles at Procter Gamble from 1980 to 2004. Mr. Aguirre is currently on the boards of directors of CVS Health,a publicly-traded American healthcare company that owns CVS Pharmacy, CVS Caremark, and Aetna; and Barry Callebaut,a publicly-traded company which is one of the world's largest cocoa processors and chocolate manufacturers. He previous served on other boards including Aetna, Inc., Coca-Cola Enterprises and Levi Strauss Co. Mr. Aguirre is currently the Owner CEO of the Erie SeaWolves Minor League Baseball team, the double AA affiliate of the Detroit Tigers. He also owns a minority stake in theMyrtle Beach Pelicans,a low A affiliate of the Chicago Cubs.A native of Mexico, Mr. Aguirre is a prominent figure in the Hispanic community, recognized as one of the 100 Influentials by Hispanic Business Magazine and honored with the Hispanic Heritage Leadership Award by the NFL. Mr. Aguirre received a B.S. from Southern Illinois University Edwardsville. - Fernando Aguirre从2004年1月至2012年10月担任Chiquita Brands International, Inc.（消费产品的全球经销商）的总裁兼首席执行官，2004年5月至2012年10月担任主席。加入Chiquita之前，他在The Procter & Gamble Company（P&G）（消费产品的制造商和分销商）的品牌管理、综合管理和转场领域工作超过23年。他于1980年开始他在P&G的职业生涯，担任各种职位，包括P&G Brazil的总裁和总经理，P&G Mexico的总裁，P&G全球零食和美国食品的副总裁，全球女性护理的总裁。他在2002年7月被任命为特殊项目的总裁，为P&G的主席和首席执行官提供报告，负责策略。他从2005年到2010年11月是Coca-Cola Enterprises Inc.的董事。
- Fernando Aguirre has been a director since July 2019. He served as President and CEO of Chiguita Brands International, Inc. from January 2004 to October 2012 and also served as Chairman from May 2004 to October 2012. Prior to that, Mr. Aguirre held various global marketing and management roles at Procter Gamble from 1980 to 2004. Mr. Aguirre is currently on the boards of directors of CVS Health,a publicly-traded American healthcare company that owns CVS Pharmacy, CVS Caremark, and Aetna; and Barry Callebaut,a publicly-traded company which is one of the world's largest cocoa processors and chocolate manufacturers. He previous served on other boards including Aetna, Inc., Coca-Cola Enterprises and Levi Strauss Co. Mr. Aguirre is currently the Owner CEO of the Erie SeaWolves Minor League Baseball team, the double AA affiliate of the Detroit Tigers. He also owns a minority stake in theMyrtle Beach Pelicans,a low A affiliate of the Chicago Cubs.A native of Mexico, Mr. Aguirre is a prominent figure in the Hispanic community, recognized as one of the 100 Influentials by Hispanic Business Magazine and honored with the Hispanic Heritage Leadership Award by the NFL. Mr. Aguirre received a B.S. from Southern Illinois University Edwardsville.
- Roger N. Farah
-
Roger N. Farah于2013年11月在公司担任执行副总裁，于2000年在公司担任公司董事。自2000年4月至2013年10月期间内他开始担任总裁兼首席操作官。他曾在维纳托集团担任董事会主席，现在在富乐客公司担任董事会主席。自1994年12月至2000年4月期间内他在维纳托集团担任首席执行官，自1994年12月至1999年8月期间内他在金融委员会担任董事长，并且是全国零售联合会执行委员会成员中的一员。现今他在安泰保险公司、进步公司以及首都银行董事会担任董事。
Roger N. Farah,previously served in executive officer positions at Ralph Lauren Corporation and Tory Burch LLC and as a director at other public companies, primarily in the retail and health insurance industries. The extensive management and operational experience Mr. Farah has in over 40 years in the retail industry enables him to provide insights, particularly in the area of customer trends, product development, brand management, and risk analysis, from a consumer-focused industry that is different than the property and casualty insurance industry. Due to his current and past service as a director of other public companies, he also has significant experience addressing the risks and corporate governance issues facing public companies, including serving as a member of their compensation, governance, and corporate social responsibility committees. Additionally, as a member of The Progressive Corporation Compensation Committee, Mr. Farah has developed a strong understanding of The Progressive Corporation culture and DEI efforts. - Roger N. Farah于2013年11月在公司担任执行副总裁，于2000年在公司担任公司董事。自2000年4月至2013年10月期间内他开始担任总裁兼首席操作官。他曾在维纳托集团担任董事会主席，现在在富乐客公司担任董事会主席。自1994年12月至2000年4月期间内他在维纳托集团担任首席执行官，自1994年12月至1999年8月期间内他在金融委员会担任董事长，并且是全国零售联合会执行委员会成员中的一员。现今他在安泰保险公司、进步公司以及首都银行董事会担任董事。
- Roger N. Farah,previously served in executive officer positions at Ralph Lauren Corporation and Tory Burch LLC and as a director at other public companies, primarily in the retail and health insurance industries. The extensive management and operational experience Mr. Farah has in over 40 years in the retail industry enables him to provide insights, particularly in the area of customer trends, product development, brand management, and risk analysis, from a consumer-focused industry that is different than the property and casualty insurance industry. Due to his current and past service as a director of other public companies, he also has significant experience addressing the risks and corporate governance issues facing public companies, including serving as a member of their compensation, governance, and corporate social responsibility committees. Additionally, as a member of The Progressive Corporation Compensation Committee, Mr. Farah has developed a strong understanding of The Progressive Corporation culture and DEI efforts.
- C. David Brown, II
-
C. David Brown, II，他自2000年以来，担任总部设在佛罗里达州奥兰多市的一家律师事务所的董事长，此前，他从1990年开始管理该公司的奥兰多办事处的执行合伙人，他于1980年加入该公司。加盟之前，他是与罗兰，鲍文和托马斯，宾夕法尼亚州一间联营公司并担任美国空军中尉。他供职于担任CVS Caremark公司的董事会，受托人为佛罗里达大学的董事会主席和奥兰多健康，一个不以营利为目的的医疗保健网络的董事会。他拥有佛罗里达大学颁发的学士和法学博士学位。
C. David Brown, II has been Chairman of Broad and Cassel, a Florida law firm, since March 2000. From 1989 until March 2000 he was Managing Partner of the Orlando office of the firm. He is also the lead director of Rayonier Advanced Materials Inc. RYAM, a leading specialty cellulose production company. Mr. Brown previously served on the board of directors and as lead director of Rayonier Inc., a real estate development and timberland management company, prior to the spin-off of RYAM in June 2014. He also served as a director of ITT Educational Services, Inc., a national provider of technology-oriented undergraduate and graduate degree programs, from April 2015 until September 2016. Mr. Brown also previously served on the board of Caremark Rx, Inc. from March 2001 until the closing of the merger transaction involving CVS Health and Caremark, when he became a director of CVS Health. - C. David Brown, II，他自2000年以来，担任总部设在佛罗里达州奥兰多市的一家律师事务所的董事长，此前，他从1990年开始管理该公司的奥兰多办事处的执行合伙人，他于1980年加入该公司。加盟之前，他是与罗兰，鲍文和托马斯，宾夕法尼亚州一间联营公司并担任美国空军中尉。他供职于担任CVS Caremark公司的董事会，受托人为佛罗里达大学的董事会主席和奥兰多健康，一个不以营利为目的的医疗保健网络的董事会。他拥有佛罗里达大学颁发的学士和法学博士学位。
- C. David Brown, II has been Chairman of Broad and Cassel, a Florida law firm, since March 2000. From 1989 until March 2000 he was Managing Partner of the Orlando office of the firm. He is also the lead director of Rayonier Advanced Materials Inc. RYAM, a leading specialty cellulose production company. Mr. Brown previously served on the board of directors and as lead director of Rayonier Inc., a real estate development and timberland management company, prior to the spin-off of RYAM in June 2014. He also served as a director of ITT Educational Services, Inc., a national provider of technology-oriented undergraduate and graduate degree programs, from April 2015 until September 2016. Mr. Brown also previously served on the board of Caremark Rx, Inc. from March 2001 until the closing of the merger transaction involving CVS Health and Caremark, when he became a director of CVS Health.
- Michael F. Mahoney
-
Michael F. Mahoney，自2012年11月起担任公司总裁、首席执行官兼董事。2011年10月17日起直到其现任职位期间，他担任公司总裁。作为公司的董事长，他专门负责心脏节律管理业务和内镜企业业务，以及某些固定企业要求。在加入该公司前， 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席，负责监督50000名员工和专营七家公司。2007年4月至2011年1月，Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长，负责骨科和神经科学业务。2001年1月至2007年3月，Mahoney先生担任全球医疗护理用品交易所（ GHX ）总裁兼首席执行官，这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团，在那里他工作了12年，最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。
Michael F. Mahoney,has been the President of Boston Scientific Corporation ("Boston Scientific"; NYSE: BSX), a global developer, manufacturer and marketer of medical devices, since October 2011, and has been Chief Executive Officer and a member of the Board of Directors of Boston Scientific since November 2012. He became Chairman of the Board of Directors of Boston Scientific in May 2016. Prior to joining Boston Scientific, Mr. Mahoney served as Worldwide Company Group Chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, he served as President and Chief Executive Officer of Global Healthcare Exchange, a leading medical supply chain solutions company. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business. Mr. Mahoney has a bachelor's degree in Finance from the University of Iowa and an M.B.A. from Wake Forest University. From October 2015 until September 2023, Mr. Mahoney served as a member of the Board of Directors of Baxter International Inc. (NYSE: BAX), a multinational health care company. He is currently a member of the Board of Directors of the Boys and Girls Club of Boston, a member of the American Heart Association CEO Roundtable, and is Chair of the Board of Governors of the Boston College Chief Executives Club. - Michael F. Mahoney，自2012年11月起担任公司总裁、首席执行官兼董事。2011年10月17日起直到其现任职位期间，他担任公司总裁。作为公司的董事长，他专门负责心脏节律管理业务和内镜企业业务，以及某些固定企业要求。在加入该公司前， 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席，负责监督50000名员工和专营七家公司。2007年4月至2011年1月，Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长，负责骨科和神经科学业务。2001年1月至2007年3月，Mahoney先生担任全球医疗护理用品交易所（ GHX ）总裁兼首席执行官，这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团，在那里他工作了12年，最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。
- Michael F. Mahoney,has been the President of Boston Scientific Corporation ("Boston Scientific"; NYSE: BSX), a global developer, manufacturer and marketer of medical devices, since October 2011, and has been Chief Executive Officer and a member of the Board of Directors of Boston Scientific since November 2012. He became Chairman of the Board of Directors of Boston Scientific in May 2016. Prior to joining Boston Scientific, Mr. Mahoney served as Worldwide Company Group Chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, he served as President and Chief Executive Officer of Global Healthcare Exchange, a leading medical supply chain solutions company. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business. Mr. Mahoney has a bachelor's degree in Finance from the University of Iowa and an M.B.A. from Wake Forest University. From October 2015 until September 2023, Mr. Mahoney served as a member of the Board of Directors of Baxter International Inc. (NYSE: BAX), a multinational health care company. He is currently a member of the Board of Directors of the Boys and Girls Club of Boston, a member of the American Heart Association CEO Roundtable, and is Chair of the Board of Governors of the Boston College Chief Executives Club.
- Nancy Ann M. DeParle
-
Nancy Ann M. DeParle她自2013年8月起出任私人股权投资公司调和Capital Partners LLC联合创始人合伙人。她自2013年8月起出任私人股权投资公司Consonance Capital Partners, LLC联合创始人合伙人。该公司为一家专注于投资小型和中等规模的医疗保健公司。2009年3月至2013年1月，她供职于白宫，首先作为总统顾问，后来任白宫健康改革办公室主任，离职前任总统及副参谋长政策助理。此外， 1993至2000年，她曾经担任白宫办公室管理和预算办公室健康和人员副主任，后来作为医疗保险中心和医疗补助服务处管理员。2001年到2009年3月，她曾任摩根大通 高级顾问和CCMP Capital, L.L.C的常务董事。CCMP Capital, L.L.C专于面向医疗保健公司私募股权投资。 她现任医疗保健服务公司HCA控股公司董事，该公司拥有，管理或经营医院与其他医疗机构。
Nancy Ann M. DeParle,is a co-founder of Consonance Capital Partners, a private equity firm, and has also served as a managing partner of the firm since January 2020. She previously served as a partner of the firm from 2013 to 2019. From March 2009 to January 2013, Ms. DeParle served in the White House, first as Counselor to the President and Director of the White House Office of Health Reform, and later as Assistant to the President and Deputy Chief of Staff for Policy. From 2001 to 2009, Ms. DeParle was a senior advisor and managing director of JPMorgan Partners and its successor, CCMP Capital. From 1993 to 2000, Ms. DeParle served as the Associate Director for Health and Personnel for the White House Office of Management and Budget, and later as the Administrator of the Centers for Medicare and Medicaid Services (then known as the Health Care Financing Administration). Ms. DeParle has also served as a director of CVS Health Corporation since September 2013. - Nancy Ann M. DeParle她自2013年8月起出任私人股权投资公司调和Capital Partners LLC联合创始人合伙人。她自2013年8月起出任私人股权投资公司Consonance Capital Partners, LLC联合创始人合伙人。该公司为一家专注于投资小型和中等规模的医疗保健公司。2009年3月至2013年1月，她供职于白宫，首先作为总统顾问，后来任白宫健康改革办公室主任，离职前任总统及副参谋长政策助理。此外， 1993至2000年，她曾经担任白宫办公室管理和预算办公室健康和人员副主任，后来作为医疗保险中心和医疗补助服务处管理员。2001年到2009年3月，她曾任摩根大通 高级顾问和CCMP Capital, L.L.C的常务董事。CCMP Capital, L.L.C专于面向医疗保健公司私募股权投资。 她现任医疗保健服务公司HCA控股公司董事，该公司拥有，管理或经营医院与其他医疗机构。
- Nancy Ann M. DeParle,is a co-founder of Consonance Capital Partners, a private equity firm, and has also served as a managing partner of the firm since January 2020. She previously served as a partner of the firm from 2013 to 2019. From March 2009 to January 2013, Ms. DeParle served in the White House, first as Counselor to the President and Director of the White House Office of Health Reform, and later as Assistant to the President and Deputy Chief of Staff for Policy. From 2001 to 2009, Ms. DeParle was a senior advisor and managing director of JPMorgan Partners and its successor, CCMP Capital. From 1993 to 2000, Ms. DeParle served as the Associate Director for Health and Personnel for the White House Office of Management and Budget, and later as the Administrator of the Centers for Medicare and Medicaid Services (then known as the Health Care Financing Administration). Ms. DeParle has also served as a director of CVS Health Corporation since September 2013.
- J. Scott Kirby
-
J. Scott Kirby，他自2013年12月起担任AAG美国公司总裁，此前，他曾担任美国航空的总裁。2006年被命名为美国航空公司总裁之前，他曾是美国航空公司销售和营销部执行副总裁，该公司与美国西部航空公司兼并之前他曾于美国西部航空公司担任该职务。他于1995年加入了美国西部航空公司，出任调度和规划部高级总监，后于1997年晋升为策划部副总裁。他于1998被任命为收入管理部副总裁，2000年早期被任命为电子商务高级副总裁。早在加入美西公司之前，他曾任职于美国航空公司决策技术公司（美国航空公司的子公司），加盟AADT公司之前曾供职于五角大楼。
J. Scott Kirby,has served as Chief Executive Officer of UAL and United since May 2020. Mr. Kirby served as President of UAL and United from August 2016 to May 2020. Prior to joining the Company, from December 2013 to August 2016, Mr. Kirby served as President of American Airlines Group and American Airlines, Inc. Mr. Kirby also previously served as President of US Airways from October 2006 to December 2013. Mr. Kirby held significant other leadership roles at US Airways and at America West prior to the 2005 merger of those carriers, including Executive Vice President—Sales and Marketing (2001 to 2006); Senior Vice President, e-business (2000 to 2001); Vice President, Revenue Management (1998 to 2000); Vice President, Planning (1997 to 1998); and Senior Director, Scheduling and Planning (1995 to 1998). Prior to joining America West, Mr. Kirby worked for American Airlines Decision Technologies and at the Pentagon. - J. Scott Kirby，他自2013年12月起担任AAG美国公司总裁，此前，他曾担任美国航空的总裁。2006年被命名为美国航空公司总裁之前，他曾是美国航空公司销售和营销部执行副总裁，该公司与美国西部航空公司兼并之前他曾于美国西部航空公司担任该职务。他于1995年加入了美国西部航空公司，出任调度和规划部高级总监，后于1997年晋升为策划部副总裁。他于1998被任命为收入管理部副总裁，2000年早期被任命为电子商务高级副总裁。早在加入美西公司之前，他曾任职于美国航空公司决策技术公司（美国航空公司的子公司），加盟AADT公司之前曾供职于五角大楼。
- J. Scott Kirby,has served as Chief Executive Officer of UAL and United since May 2020. Mr. Kirby served as President of UAL and United from August 2016 to May 2020. Prior to joining the Company, from December 2013 to August 2016, Mr. Kirby served as President of American Airlines Group and American Airlines, Inc. Mr. Kirby also previously served as President of US Airways from October 2006 to December 2013. Mr. Kirby held significant other leadership roles at US Airways and at America West prior to the 2005 merger of those carriers, including Executive Vice President—Sales and Marketing (2001 to 2006); Senior Vice President, e-business (2000 to 2001); Vice President, Revenue Management (1998 to 2000); Vice President, Planning (1997 to 1998); and Senior Director, Scheduling and Planning (1995 to 1998). Prior to joining America West, Mr. Kirby worked for American Airlines Decision Technologies and at the Pentagon.
- Jeffrey R. Balser
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Karen S. Lynch
Karen S. Lynch，是Aetna Inc.（一家多元医疗保健利益公司）总裁。她自2014年起担任总裁。她从2013年到2014年担任Aetna's Local and Regional业务执行副总裁；2012年到2013年担任Aetna's Specialty Products业务执行副总裁。Lynch从2009年到2012年担任Magellan Health Services Inc.（一家医疗保健管理公司）总裁。加入Magellan Health之前，她从1999年到2009年在Cigna Corporation（一家全球健康保险服务公司）担任多个领导职位。
Karen S. Lynch,President and Chief Executive Officer of CVS Health Corporation since February 2021; Executive Vice President of CVS Health Corporation from November 2018 through January 2021; President of Aetna Inc. from January 2015 through January 2021; and a director of CVS Health Corporation since February 2021.- Karen S. Lynch，是Aetna Inc.（一家多元医疗保健利益公司）总裁。她自2014年起担任总裁。她从2013年到2014年担任Aetna's Local and Regional业务执行副总裁；2012年到2013年担任Aetna's Specialty Products业务执行副总裁。Lynch从2009年到2012年担任Magellan Health Services Inc.（一家医疗保健管理公司）总裁。加入Magellan Health之前，她从1999年到2009年在Cigna Corporation（一家全球健康保险服务公司）担任多个领导职位。
- Karen S. Lynch,President and Chief Executive Officer of CVS Health Corporation since February 2021; Executive Vice President of CVS Health Corporation from November 2018 through January 2021; President of Aetna Inc. from January 2015 through January 2021; and a director of CVS Health Corporation since February 2021.
- James D. Clark
James D. Clark自2018年11月起担任CVS Health Corporation高级副总裁-财务总监兼首席会计官James D.Clark； 从2009年9月至2018年10月，CVS Pharmacy，Inc.财务和会计副总裁。
James D. Clark,Controller and Chief Accounting Officer of CVS Health Corporation since November 2018; Vice President - Finance and Accounting of CVS Pharmacy, Inc. from September 2009 through October 2018.- James D. Clark自2018年11月起担任CVS Health Corporation高级副总裁-财务总监兼首席会计官James D.Clark； 从2009年9月至2018年10月，CVS Pharmacy，Inc.财务和会计副总裁。
- James D. Clark,Controller and Chief Accounting Officer of CVS Health Corporation since November 2018; Vice President - Finance and Accounting of CVS Pharmacy, Inc. from September 2009 through October 2018.
- Laurie P. Havanec
Laurie P. Havanec，自2021年2月起担任CVS Health Corporation执行副总裁兼首席人事官；自2019年10月至2021年1月担任电梯、自动扶梯和自动人行道制造商奥的斯全球公司执行副总裁兼首席人事官；公司副总裁，2019年4月至2019年10月，担任跨国制造集团联合技术公司（United Technologies Corporation）的人才；2013年至2017年3月，担任安泰保险机构业务部人力资源副总裁。
Laurie P. Havanec,Executive Vice President and Chief People Officer of CVS Health Corporation since February 2021; Executive Vice President and Chief People Officer, Otis Worldwide Corporation, an elevator, escalator and moving walkway manufacturer, from October 2019 through January 2021; Corporate Vice President, Talent of United Technologies Corporation, a multinational manufacturing conglomerate, from April 2017 through October 2019; Vice President - Human Resources, Institution Businesses of Aetna Inc. from 2013 through March 2017. Ms. Havanec is also a member of the board of directors of American Water Works Company, Inc., a publicly traded water and wastewater utility company.- Laurie P. Havanec，自2021年2月起担任CVS Health Corporation执行副总裁兼首席人事官；自2019年10月至2021年1月担任电梯、自动扶梯和自动人行道制造商奥的斯全球公司执行副总裁兼首席人事官；公司副总裁，2019年4月至2019年10月，担任跨国制造集团联合技术公司（United Technologies Corporation）的人才；2013年至2017年3月，担任安泰保险机构业务部人力资源副总裁。
- Laurie P. Havanec,Executive Vice President and Chief People Officer of CVS Health Corporation since February 2021; Executive Vice President and Chief People Officer, Otis Worldwide Corporation, an elevator, escalator and moving walkway manufacturer, from October 2019 through January 2021; Corporate Vice President, Talent of United Technologies Corporation, a multinational manufacturing conglomerate, from April 2017 through October 2019; Vice President - Human Resources, Institution Businesses of Aetna Inc. from 2013 through March 2017. Ms. Havanec is also a member of the board of directors of American Water Works Company, Inc., a publicly traded water and wastewater utility company.
- Prem Shah
Prem Shah自2021年11月起担任CVS健康公司执行副总裁兼首席药剂师，自2022年1月起担任零售部副总裁；执行副总裁，专业和产品创新CVS CARMARK从2018年8月到2021年11月；2013年2月至2018年7月任CVS Caremark专业药房副总裁。
Prem Shah,Executive Vice President and Chief Pharmacy Officer of CVS Health Corporation since November 2021 and Co-President of Retail since January 2022; Executive Vice President, Specialty and Product Innovation, CVS Caremark from August 2018 through November 2021; Vice President - Specialty Pharmacy, CVS Caremark from February 2013 through July 2018.- Prem Shah自2021年11月起担任CVS健康公司执行副总裁兼首席药剂师，自2022年1月起担任零售部副总裁；执行副总裁，专业和产品创新CVS CARMARK从2018年8月到2021年11月；2013年2月至2018年7月任CVS Caremark专业药房副总裁。
- Prem Shah,Executive Vice President and Chief Pharmacy Officer of CVS Health Corporation since November 2021 and Co-President of Retail since January 2022; Executive Vice President, Specialty and Product Innovation, CVS Caremark from August 2018 through November 2021; Vice President - Specialty Pharmacy, CVS Caremark from February 2013 through July 2018.
- Tilak Mandadi
Tilak Mandadi ，自2021年7月以来，一直担任首席战略、创新和技术官员。在加入公司之前，Mandadi先生从2013年3月起担任迪士尼乐园、体验和产品有限公司的数字和全球首席技术官执行副总裁。在加入迪士尼之前，Mandadi曾于2006年7月至2013年3月担任美国运通公司的数字高级副总裁。
Tilak Mandadi,Executive Vice President and Chief Data, Digital and Technology Officer of CVS Health Corporation since July 2022; Chief Strategy Officer, MGM Resorts International from July 2021 through July 2022; Executive Vice President, Digital & Global Chief Technology Officer, Disney Parks, Experiences and Products from March 2013 through July 2021.- Tilak Mandadi ，自2021年7月以来，一直担任首席战略、创新和技术官员。在加入公司之前，Mandadi先生从2013年3月起担任迪士尼乐园、体验和产品有限公司的数字和全球首席技术官执行副总裁。在加入迪士尼之前，Mandadi曾于2006年7月至2013年3月担任美国运通公司的数字高级副总裁。
- Tilak Mandadi,Executive Vice President and Chief Data, Digital and Technology Officer of CVS Health Corporation since July 2022; Chief Strategy Officer, MGM Resorts International from July 2021 through July 2022; Executive Vice President, Digital & Global Chief Technology Officer, Disney Parks, Experiences and Products from March 2013 through July 2021.
- Sreekanth K. Chaguturu
Sreekanth K. Chaguturu，执行副总裁兼CVS Health Corporation首席医疗官，2022年5月至今；CVS Caremark首席医疗官，2019年9月至2022年5月；Mass General Brigham（前身为Partners HealthCare）非营利性医院，2017年8月至2019年8月担任Population Health首席医疗官；Mass General Brigham（前身为Partners HealthCare）负责Population Health管理副总裁，2014年6月至2017年8月。Chaguturu博士也是麻省总医院的主治医师和哈佛医学院的内科讲师，从2007年7月至今。
Sreekanth K. Chaguturu,Executive Vice President and Chief Medical Officer of CVS Health Corporation since May 2022; Chief Medical Officer of CVS Caremark from September 2019 through May 2022; Chief Population Health Officer at Mass General Brigham, a non-profit hospital formerly known as Partners HealthCare, from August 2017 through August 2019; Vice President, Population Health Management at Mass General Brigham from June 2014 through August 2017. Dr. Chaguturu is also an Attending Physician at Massachusetts General Hospital and an Instructor in Internal Medicine at Harvard Medical School from July 2007 to the present.- Sreekanth K. Chaguturu，执行副总裁兼CVS Health Corporation首席医疗官，2022年5月至今；CVS Caremark首席医疗官，2019年9月至2022年5月；Mass General Brigham（前身为Partners HealthCare）非营利性医院，2017年8月至2019年8月担任Population Health首席医疗官；Mass General Brigham（前身为Partners HealthCare）负责Population Health管理副总裁，2014年6月至2017年8月。Chaguturu博士也是麻省总医院的主治医师和哈佛医学院的内科讲师，从2007年7月至今。
- Sreekanth K. Chaguturu,Executive Vice President and Chief Medical Officer of CVS Health Corporation since May 2022; Chief Medical Officer of CVS Caremark from September 2019 through May 2022; Chief Population Health Officer at Mass General Brigham, a non-profit hospital formerly known as Partners HealthCare, from August 2017 through August 2019; Vice President, Population Health Management at Mass General Brigham from June 2014 through August 2017. Dr. Chaguturu is also an Attending Physician at Massachusetts General Hospital and an Instructor in Internal Medicine at Harvard Medical School from July 2007 to the present.
- Thomas F. Cowhey
Thomas F. Cowhey，自2022年2月加入公司以来，他一直担任Cvs Health Corporation资本市场高级副总裁，最近扩大了他的角色，包括监督更广泛的公司财务职能。在加入CVS Health之前，Cowhey先生从2018年4月到2022年2月担任医疗服务公司Surgery Partners的执行副总裁兼首席财务官。在此之前，他曾在Aetna、Legacy Partners Group和Credit Suisse的医疗保健和并购集团担任领导职务。
Thomas F. Cowhey,Executive Vice President and Chief Financial Officer of CVS Health Corporation since January 2024; Interim Chief Financial Officer of CVS Health Corporation from October 2023 through January 2024; Senior Vice President, Corporate Finance of CVS Health Corporation from September 2023 through October 2023; Senior Vice President, Capital Markets of CVS Health Corporation from February 2022 through September 2023; and Executive Vice President and Chief Financial Officer of Surgical Partners, a large independent operator of short-stay surgical facilities, from April 2018 through February 2022.- Thomas F. Cowhey，自2022年2月加入公司以来，他一直担任Cvs Health Corporation资本市场高级副总裁，最近扩大了他的角色，包括监督更广泛的公司财务职能。在加入CVS Health之前，Cowhey先生从2018年4月到2022年2月担任医疗服务公司Surgery Partners的执行副总裁兼首席财务官。在此之前，他曾在Aetna、Legacy Partners Group和Credit Suisse的医疗保健和并购集团担任领导职务。
- Thomas F. Cowhey,Executive Vice President and Chief Financial Officer of CVS Health Corporation since January 2024; Interim Chief Financial Officer of CVS Health Corporation from October 2023 through January 2024; Senior Vice President, Corporate Finance of CVS Health Corporation from September 2023 through October 2023; Senior Vice President, Capital Markets of CVS Health Corporation from February 2022 through September 2023; and Executive Vice President and Chief Financial Officer of Surgical Partners, a large independent operator of short-stay surgical facilities, from April 2018 through February 2022.
- Brian A. Kane
Brian A. Kane，自2023年9月起担任西维斯健康公司执行副总裁兼Aetna总裁；于2022年6月至2023年9月担任专注于医疗保健服务的私募股权公司的独立战略顾问；于2014年6月至2021年5月担任上市的健康和福祉公司哈门那，Inc.的首席财务官的TERM2。
Brian A. Kane,Executive Vice President of CVS Health Corporation and President of Aetna since September 2023; Independent Strategic Advisor to private equity firms focused on health care services from June 2022 to September 2023; and Chief Financial Officer of Humana, Inc., a publicly traded health and well-being company, from June 2014 through May 2021.- Brian A. Kane，自2023年9月起担任西维斯健康公司执行副总裁兼Aetna总裁；于2022年6月至2023年9月担任专注于医疗保健服务的私募股权公司的独立战略顾问；于2014年6月至2021年5月担任上市的健康和福祉公司哈门那，Inc.的首席财务官的TERM2。
- Brian A. Kane,Executive Vice President of CVS Health Corporation and President of Aetna since September 2023; Independent Strategic Advisor to private equity firms focused on health care services from June 2022 to September 2023; and Chief Financial Officer of Humana, Inc., a publicly traded health and well-being company, from June 2014 through May 2021.
- J. David Joyner
J. David Joyner，2011年3月起出任CVS Caremark Corporation执行副总裁，2004年3月起，出任 CVS Caremark Pharmacy Services营销和会计服务部执行副总裁。
J. David Joyner,Executive Vice President of CVS Health Corporation and President of Pharmacy Services since January 2023; Strategic Business Advisor to gWell, Inc., a wellness technology company, since July 2021; Advisor to Podimetrics Inc., a health care company focused on the identification and treatment of diabetic foot ulcers since September 2020; Advisory Council to the Rawls College of Business of Texas Tech University since July 2020; Executive Vice President – Sales and Account Services, CVS Caremark for CVS Health Corporation from March 2011 through December 2019.- J. David Joyner，2011年3月起出任CVS Caremark Corporation执行副总裁，2004年3月起，出任 CVS Caremark Pharmacy Services营销和会计服务部执行副总裁。
- J. David Joyner,Executive Vice President of CVS Health Corporation and President of Pharmacy Services since January 2023; Strategic Business Advisor to gWell, Inc., a wellness technology company, since July 2021; Advisor to Podimetrics Inc., a health care company focused on the identification and treatment of diabetic foot ulcers since September 2020; Advisory Council to the Rawls College of Business of Texas Tech University since July 2020; Executive Vice President – Sales and Account Services, CVS Caremark for CVS Health Corporation from March 2011 through December 2019.
- Samrat S. Khichi
Samrat S. Khichi自2007年10月担任C. R. Bard, Inc.高级副总裁、法律总顾问以及秘书长。2014年7月至2017年12月为C.R. Bard，Inc.高级副总裁，法律总顾问兼公司秘书；在此之前，曾任黑石集团旗下投资公司Catalent Pharma Solutions首席行政官，高级副总裁，总法律顾问兼秘书。在2011年，Khichi先生还被任命为首席行政官。在此之前，Khichi先生是O’Melveny & Myers公司旗下私人实体集团和并购部门的顾问。在加入O’Melveny & Myers公司前，Khichi先生被乔治布什总统任命为白宫学者。在此任命之前，Khichi先生还在McDermott Will & Emery律师事务所和思特灵律师事务所旗下的并购部门担任律师。Khichi先生曾在军队服役，包括担任美军现役野战炮兵军官、海军预备役少校以及陆军国民警卫队上尉。Khichi先生任职于新泽西陆军国民警卫队药物项目时，还担任纽约/新泽西高强度毒品走私部门的副局长。Khichi先生从乔治城大学获得理学学士学位，从西北大学凯洛格管理学院获得工商管理学硕士学位，从福特汉姆大学法学院以法学院优等生和最优成绩获得法学博士学位。
Samrat S. Khichi, Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel since September 2021; Executive Vice President, Public Policy, Regulatory Affairs and General Counsel from May 2019 to September 2021; Executive Vice President and General Counsel from December 2017 to May 2019; and Senior Vice President, General Counsel and Corporate Secretary, C.R. Bard, Inc. from July 2014 to December 2017.- Samrat S. Khichi自2007年10月担任C. R. Bard, Inc.高级副总裁、法律总顾问以及秘书长。2014年7月至2017年12月为C.R. Bard，Inc.高级副总裁，法律总顾问兼公司秘书；在此之前，曾任黑石集团旗下投资公司Catalent Pharma Solutions首席行政官，高级副总裁，总法律顾问兼秘书。在2011年，Khichi先生还被任命为首席行政官。在此之前，Khichi先生是O’Melveny & Myers公司旗下私人实体集团和并购部门的顾问。在加入O’Melveny & Myers公司前，Khichi先生被乔治布什总统任命为白宫学者。在此任命之前，Khichi先生还在McDermott Will & Emery律师事务所和思特灵律师事务所旗下的并购部门担任律师。Khichi先生曾在军队服役，包括担任美军现役野战炮兵军官、海军预备役少校以及陆军国民警卫队上尉。Khichi先生任职于新泽西陆军国民警卫队药物项目时，还担任纽约/新泽西高强度毒品走私部门的副局长。Khichi先生从乔治城大学获得理学学士学位，从西北大学凯洛格管理学院获得工商管理学硕士学位，从福特汉姆大学法学院以法学院优等生和最优成绩获得法学博士学位。
- Samrat S. Khichi, Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel since September 2021; Executive Vice President, Public Policy, Regulatory Affairs and General Counsel from May 2019 to September 2021; Executive Vice President and General Counsel from December 2017 to May 2019; and Senior Vice President, General Counsel and Corporate Secretary, C.R. Bard, Inc. from July 2014 to December 2017.